В реальном времени·Открытые вопросы в исследованиях долголетия

Sam Altman

No public longevity impact is supported here. The only cited paper is by Soya S Sam on an HIV assay, not Sam Altman, so crediting Altman would be spreadsheet cosplay.

9 / 100investorself-experimenterScoring AI engine · v0.4.0
Role
investorhigh confidence

This is the actual channel: he put very large equity capital into Retro Biosciences and seeded the company. Delete the money and most of his longevity impact here disappears.

Inside the AI used by Sam Altman's $1B+ longevity startupInside the AI used by Sam Altm…–Free Radicals – Apple Podcas

also: self-experimenter

Разбивка по измерениям

Этот балл оценивает только приверженность долголетию. Метки роли выше — scientist, investor и остальные — показывают, кем является этот человек; мы не оцениваем их отдельно.

Об этом человеке пока собрано мало данных. До сбора дополнительных материалов оценки сопровождаются предупреждениями о низкой достоверности.

Видение будущего

0.0/ 10

The dimension applies, but the provided evidence contains no articulated vision from Sam Altman about ending aging, reversing biological decline, or materially extending healthy lifespan. The only relevant signal is a broad investor bio mentioning a longevity biotech investment footprint, which does not establish a concrete or durable public future vision.

high уверенность

Научное влияние

1.0/ 10

There is no credible evidence of Sam Altman's direct scientific output or field-shaping scientific influence in the provided evidence. The only academic citation appears to be for a different person named Soya S Sam, not Sam Altman. The investor bio suggests exposure to longevity biotech and related sectors, but provides no specific scientific achievements, citations, authored work, trials, or independently corroborated translational impact.

low уверенность

Вложенный капитал

1.0/ 10

The dimension applies because Sam Altman is described as an investor with substantial capacity, but the provided evidence contains no specific longevity investments, donations, amounts, institutions, recurring commitments, or catalytic funding. A weak dossier statement says his investment footprint spans longevity biotech, but it gives no names or amounts and has unknown independence, so it cannot support more than a very low score.

low уверенность

Качество стратегических решений

1.0/ 10

The dimension applies because Sam Altman is described as an entrepreneur and investor, but the supplied evidence contains almost no concrete longevity-related strategic bets, thesis, timing, stage preference, or counterfactual contribution. A generic statement that his public investment footprint spans longevity biotech is too thin to establish thesis-coherent, early, contrarian, or field-improving strategic taste.

low уверенность

Создание направления

1.0/ 10

The dimension is applicable, but the provided evidence contains no credible longevity-specific field_creation achievements by Sam Altman. The structured facts report no founded organizations, active organizations, or donation-created programs, and the only relevant biographical note is too general to show he created longevity institutions, programs, categories, communities, protocols, or funding paths.

low уверенность

Смелость и убеждённость

0.0/ 10

The provided evidence does not show any public longevity-related risk-taking, contrarian advocacy, career sacrifice, sustained conviction under criticism, unusually large bet relative to capacity, or self-experimentation by Sam Altman. A broad investment footprint that includes longevity biotech is not enough to establish bravery or conviction under this rubric.

medium уверенность

Эффект множителя

2.0/ 10

The dimension is applicable, but the supplied evidence contains almost no concrete longevity-specific multiplier effects. One dossier-style source says Altman has a broad investment footprint that includes longevity biotech, but it does not identify specific longevity investments, organizations, collaborators, follow-on projects, or independently corroborated field-level leverage.

low уверенность
Видение будущего

Цель

He reportedly helped Betts- LaCroix shape the company’s ten- year longevity goal during an off- site retreat at Altman’s ranch in Napa Valley, according to Endpoint News.

[S1] Medium 2025

He reportedly helped Betts- LaCroix shape the company’s ten- year longevity goal during an off- site retreat at Altman’s ranch in Napa Valley, according to Endpoint News.

[S2] Medium 2025

Altman’s involvement with Retro runs deep. He reportedly helped Betts- LaCroix shape the company’s ten- year longevity goal during an off- site retreat at Altman’s ranch in Napa Valley, according to Endpoint News.

[S3] High 2025

Sam Altman’s Retro Biosciences Aims to Add a Decade to Human Life

[S4] High 2025

I hope to use a Retro therapy someday!

[S5] High 2023

He says he’s emptied his bank account to fund two other very different but equally ambitious goals: limitless energy and extended life span.

[S6] High 2023

He says he’s emptied his bank account to fund two other very different but equally ambitious goals: limitless energy and extended life span.

[S7] High 2023

He says he’s emptied his bank account to fund two other very different but equally ambitious goals: limitless energy and extended life span.

[S8] High 2023

Путь

No canonical quotes yet.

Стратегия

No strategy evidence was available for Sam Altman in the provided materials. Investment, donation, and organization-founding records are unsupported here. Stage preference, area focus, geography focus, risk appetite, and time horizon are therefore unknown. No collaborators or notable longevity-related bets can be identified from the supplied evidence.

UnknownUnknown
Портфель

Пожертвования

No public rows yet.

Основанные организации

No public rows yet.

Научные результаты
h-index-
Citations-
Papers1
Trials0
Смелость и убеждённость
Изменение взглядов
“The main thing for Retro is to be a really good bio startup, because that is a rare thing,” says Altman. “It’s combining great science and the resources of a big company with the spirit of a startup that gets things done. And that is the project for now.“Longevity path thesis · 2023 · “The main thing for Retro is to be a really good bio startup, because that is a rare thing,” says Altman. “It’s combining great science and the resources of a big company with the spirit of a startup that gets things done. And that is the project for now.“
Эксперименты на себе
Retro Biosciences backingOther · Unknown · 2021 · Sam Altman provided initial funding for Retro Biosciences, a longevity startup.
Retro Biosciences investmentOther · Active · 2021 · Committed $180 million to Retro Biosciences, a company pursuing extended human life span.
Retro Biosciences backingOther · Unknown · 2021 · Sam Altman provided an initial $180 million investment to Retro Biosciences, a longevity startup.
Retro BiosciencesStem Cell · Active · Publicly associated with a longevity startup pursuing life-extension through stem cell technology.
Retro Biosciences investmentOther · Active · Sam Altman invested in Retro Biosciences, a company developing biotechnology to combat aging and age-related diseases.
Retro Biosciences investmentOther · Active · Sam Altman publicly backed the longevity-focused company Retro Biosciences with a large personal investment.
Investment in Retro BiosciencesOther · Unknown · Sam Altman funded Retro Biosciences, a longevity startup developing therapies to prevent and reverse age-related disease.
metforminCompound · Active · Sam Altman says he takes metformin as part of his anti-aging regime.
Связи

Companies

Longevity technologyEmployee · News Roundup Sam Altman’s $1.8B Longevity Company, CRISPR & AI Health

Collaborators and lineage

No public rows yet.

Критика